Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-27T12:39:20.023Z Has data issue: false hasContentIssue false

P-1101 - Meizitang, Oestrogen Levels and Psychosis in a Transsexual - Case Report and Literature Review

Published online by Cambridge University Press:  15 April 2020

A. Mohandas
Affiliation:
Kent and Medway NHS Trust, Maidstone
O. Malik
Affiliation:
Oxleas NHS Trust
B.B. Roy
Affiliation:
Oxleas NHS Trust South London & Maudsley Trust, London, UK

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The authors would like to report on, what we believe is the first reported case in the United Kingdom, of a 29 year old transsexual, who developed an acute psychotic episode due to a fall in Oestrogen levels and intake of Meizitang. We discuss the aetiology of his presentation, the protective effects of Oestrogen and the psychotic effects of Meizitang.

Methods

Case-report, Literature review and Discussion.

Results & case report

AB was a 29 year old transsexual admitted with a two week history of paranoid delusions and auditory hallucinations. He had recently reduced his Oestrogen tablets from 4 mg to 2 mg per day. He had also been taking Meizitang “a natural herbal” slimming pill, bought online. He presented with paranoid, persecutory delusions, first and third person auditory hallucinations and poor insight. He was treated with Quetiapine, recovered completely within 2 weeks and was discharged.

Discussion

We propose that the reduction in Oestrogen levels, the intake of Meizitang and the cognitive dissonance associated with his gender identity contributed to the development of psychosis. Our literature review revealed several studies that implicated Sibutramine (which Meizitang is known to be adulterated with) as an aetiological factor for psychosis. We also report on studies that demonstrated the anti-psychotic effects of Oestrogen.

Conclusion

This case highlights the need for further studies on both the protective effects of Oestrogen in psychosis and the psychogenic effects of Meizitang. We recommend increased awareness amongst clinicians about the potential risk of psychosis associated with Meizitang.

Type
Abstract
Copyright
Copyright © European Psychiatric Association 2012
Submit a response

Comments

No Comments have been published for this article.